These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10496841)

  • 21. [Heparin and cancer].
    Lykke J
    Ugeskr Laeger; 2006 Dec; 168(50):4397-401. PubMed ID: 17217864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 25. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence.
    Cosgrove RH; Zacharski LR; Racine E; Andersen JC
    Semin Thromb Hemost; 2002 Feb; 28(1):79-87. PubMed ID: 11885028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International normalized ratio and anticoagulation.
    Theerman MR
    Arch Intern Med; 2003 May; 163(10):1242-3; author reply 1244. PubMed ID: 12767971
    [No Abstract]   [Full Text] [Related]  

  • 28. Low-molecular-weight heparin in oncology.
    Zacharski LR; Loynes JT
    Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombotic therapy in cancer.
    Lemoine NR
    J Clin Oncol; 2005 Apr; 23(10):2119-20. PubMed ID: 15699474
    [No Abstract]   [Full Text] [Related]  

  • 30. Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolism.
    Prandoni P
    J Support Oncol; 2006 Mar; 4(3):127-8. PubMed ID: 16553138
    [No Abstract]   [Full Text] [Related]  

  • 31. Low-molecular-weight heparins in the management of cardiovascular conditions.
    Kayser SR
    Prog Cardiovasc Nurs; 1998; 13(1):34-40. PubMed ID: 9614687
    [No Abstract]   [Full Text] [Related]  

  • 32. Low molecular weight heparins in cardiovascular medicine.
    De Lorenzo F; Dotsenko O; Kakkar VV
    Minerva Cardioangiol; 2005 Dec; 53(6):585-603. PubMed ID: 16333240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of deep vein thrombosis using low-molecular-weight heparins.
    Groce JB
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
    Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
    Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-molecular-weight heparin and survival in patients with malignant disease.
    Kakkar AK
    Cancer Control; 2005 Sep; 12 Suppl 1():22-30. PubMed ID: 16179901
    [No Abstract]   [Full Text] [Related]  

  • 36. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.
    Hettiarachchi RJ; Smorenburg SM; Ginsberg J; Levine M; Prins MH; Büller HR
    Thromb Haemost; 1999 Aug; 82(2):947-52. PubMed ID: 10605808
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
    Nguyen-Ho P; Levine GN
    Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke.
    Padma V; Fisher M; Moonis M
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
    Mismetti P; Laporte-Simitsidis S; Tardy B; Cucherat M; Buchmüller A; Juillard-Delsart D; Decousus H
    Thromb Haemost; 2000 Jan; 83(1):14-9. PubMed ID: 10669147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.